Aridis Pharmaceuticals, Inc. (ARDS)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Aridis Pharmaceuticals, Inc. (ARDS) trades at $0.00 with AI Score 42/100 (Weak). Aridis Pharmaceuticals, Inc. Market cap: 9K, Sector: Healthcare.
Last analyzed: Mar 15, 2026Aridis Pharmaceuticals, Inc. (ARDS) Healthcare & Pipeline Overview
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, specializes in developing fully human monoclonal antibody-based immunotherapies for life-threatening infections. With a focus on addressing unmet needs in antibiotic resistance, Aridis is advancing its pipeline, including AR-301 in Phase III trials, targeting critical infections like Staphylococcus aureus and Pseudomonas aeruginosa.
Investment Thesis
Aridis Pharmaceuticals presents a high-risk, high-reward investment opportunity, driven by its innovative approach to combating life-threatening infections through targeted immunotherapies. The primary value driver is the successful completion of Phase III trials for AR-301, targeting S. aureus alphatoxin-mediated lung infections. Positive results and subsequent regulatory approval could lead to significant revenue generation, addressing a critical unmet need in antibiotic resistance. Further potential lies in the advancement of its pipeline, including AR-105 and AR-501, targeting Pseudomonas aeruginosa and chronic lung infections in cystic fibrosis patients, respectively. However, the company faces significant risks, including clinical trial failures, regulatory hurdles, and the need for additional capital to fund ongoing research and development. The negative beta of -26.04 suggests an inverse correlation with the market, which could provide some downside protection during market downturns, but also indicates high volatility.
Based on FMP financials and quantitative analysis
Key Highlights
- AR-301 is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, representing a significant milestone in the company's development pipeline.
- The company is developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus.
- AR-105, a fully human IgG1 mAb, is in Phase II trials to target gram-negative bacteria P. aeruginosa, expanding the company's focus beyond Staphylococcus aureus.
- Aridis Pharmaceuticals has a market capitalization of $0.00B, reflecting its current valuation in the biotechnology sector.
- The company has 37 employees, indicating a relatively small and focused team driving its research and development efforts.
Competitors & Peers
Strengths
- Innovative mAb Technology: Expertise in developing fully human monoclonal antibodies.
- Targeted Immunotherapy Approach: Focus on addressing antibiotic resistance with targeted therapies.
- Pipeline of Product Candidates: Diversified pipeline targeting various infectious diseases.
- Late-Stage Clinical Development: Lead product candidate AR-301 in Phase III trials.
Weaknesses
- Limited Financial Resources: Requires additional capital to fund ongoing research and development.
- Dependence on Clinical Trial Success: The success of its product candidates depends on positive clinical trial results.
- Regulatory Hurdles: Faces regulatory challenges in obtaining approval for its therapies.
- OTC Market Listing: Limited access to institutional investors and lower trading volume.
Catalysts
- Upcoming: AR-301 Phase III Clinical Trial Results: Anticipated data readout from Phase III trials for AR-301 in the next 12-18 months.
- Upcoming: AR-501 Clinical Trial Progress: Continued clinical development of AR-501 for chronic lung infections in cystic fibrosis patients.
- Ongoing: Potential Partnerships and Licensing Agreements: Ongoing discussions with potential partners and licensees for its mAb-based therapies.
- Ongoing: Government Funding and Grants: Potential to secure government funding and grants for research and development.
- Ongoing: Expansion into New Indications: Long-term growth strategy with potential new product launches in the next 5-10 years.
Risks
- Potential: Clinical Trial Failures: Risk of clinical trial failures that could delay or halt product development.
- Potential: Regulatory Rejection: Risk of regulatory rejection of its product candidates.
- Potential: Patent Expiration: Risk of patent expiration that could lead to generic competition.
- Ongoing: Limited Financial Resources: Requires additional capital to fund ongoing research and development.
- Ongoing: Competition from Established Pharmaceutical Companies: Faces competition from larger companies with established infectious disease portfolios.
Growth Opportunities
- AR-301 Phase III Success: Successful completion of Phase III clinical trials for AR-301 and subsequent regulatory approval represents a major growth catalyst. The market for treating S. aureus alphatoxin-mediated lung infections is substantial, with a growing need for effective therapies to combat antibiotic resistance. Timeline: Anticipated data readout from Phase III trials within the next 12-18 months. Competitive Advantage: AR-301's targeted approach offers a potential advantage over broad-spectrum antibiotics.
- Expansion of AR-501 for Cystic Fibrosis: AR-501, an anti-infective therapy in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients, represents a significant growth opportunity. The cystic fibrosis market is characterized by a high unmet need for effective therapies to manage chronic lung infections. Timeline: Continued clinical development and potential regulatory approval within the next 3-5 years. Competitive Advantage: AR-501's targeted approach could improve patient outcomes and reduce the need for antibiotics.
- Advancement of AR-105 for Pseudomonas aeruginosa: AR-105, a fully human IgG1 mAb in Phase II trials targeting gram-negative bacteria P. aeruginosa, addresses a critical need for new therapies to combat these infections. Pseudomonas aeruginosa is a leading cause of hospital-acquired infections and is increasingly resistant to antibiotics. Timeline: Continued clinical development and potential regulatory approval within the next 3-5 years. Competitive Advantage: AR-105's targeted approach could improve patient outcomes and reduce the need for broad-spectrum antibiotics.
- Partnerships and Licensing Agreements: Strategic partnerships with larger pharmaceutical companies or licensing agreements for its mAb-based therapies could provide significant financial resources and accelerate the development and commercialization of Aridis's pipeline. Timeline: Ongoing discussions with potential partners and licensees. Competitive Advantage: Aridis's innovative technology and pipeline of therapies make it an attractive partner for companies seeking to expand their infectious disease portfolios.
- Expansion into New Indications: Aridis could leverage its mAb technology platform to develop therapies for other infectious diseases or immune-related disorders, expanding its market reach and diversifying its revenue streams. Timeline: Long-term growth strategy with potential new product launches in the next 5-10 years. Competitive Advantage: Aridis's expertise in mAb development and its understanding of infectious disease biology provide a strong foundation for expanding into new therapeutic areas.
Opportunities
- Partnerships and Licensing Agreements: Potential to collaborate with larger pharmaceutical companies.
- Expansion into New Indications: Opportunity to leverage its technology platform for other diseases.
- Growing Market for Antibiotic Resistance: Increasing demand for novel therapies to combat antibiotic resistance.
- Government Funding and Grants: Potential to secure government funding and grants for research and development.
Threats
- Competition from Established Pharmaceutical Companies: Faces competition from larger companies with established infectious disease portfolios.
- Clinical Trial Failures: Risk of clinical trial failures that could delay or halt product development.
- Regulatory Rejection: Risk of regulatory rejection of its product candidates.
- Patent Expiration: Risk of patent expiration that could lead to generic competition.
Competitive Advantages
- Proprietary mAb Technology: Aridis's expertise in developing fully human monoclonal antibodies provides a competitive advantage.
- Patent Protection: Patents on its mAb-based therapies provide exclusivity and protect its market position.
- Clinical Data: Positive clinical trial data for its lead product candidates strengthens its competitive position.
- Targeted Approach: Its focus on targeted immunotherapies offers a potential advantage over broad-spectrum antibiotics.
About ARDS
Founded in 2003 and headquartered in Los Gatos, California, Aridis Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel, targeted immunotherapies. The company's core focus lies in utilizing fully human monoclonal antibodies (mAbs) to combat life-threatening infections, particularly those caused by antibiotic-resistant bacteria. Aridis's lead product candidate, AR-301, is a fully human mAb of immunoglobulin 1 (IgG1) currently in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. This therapy aims to neutralize the toxin produced by Staphylococcus aureus, a common cause of pneumonia and other severe infections. Beyond AR-301, Aridis is developing a pipeline of mAb-based therapies targeting various infectious diseases. These include AR-320, targeting S. aureus alpha toxin for methicillin-resistant and susceptible S. aureus infections; AR-105, targeting gram-negative bacteria P. aeruginosa; AR-101, targeting hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 for infections caused by Acinetobacter baumannii; AR-201 for respiratory syncytial virus; and AR-501 for chronic lung infections in cystic fibrosis patients. Additionally, Aridis is developing AR-712 and AR-701, a cocktail of mAbs for treating mild to moderate non-hospitalized COVID-19 patients.
What They Do
- Discovers and develops targeted immunotherapy solutions.
- Utilizes fully human monoclonal antibodies (mAbs) to treat life-threatening infections.
- Develops AR-301, a mAb in Phase III trials for treating lung infections from S. aureus alphatoxin.
- Creates AR-320, a mAb targeting S. aureus alpha toxin for treating methicillin-resistant and susceptible S. aureus infections.
- Advances AR-105, a mAb in Phase II trials targeting gram-negative bacteria P. aeruginosa.
- Develops AR-101, a mAb in Phase IIa clinical trials for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) caused by P. aeruginosa.
- Creates AR-501, an anti-infective therapy in Phase I/IIa clinical trial for chronic lung infections in cystic fibrosis patients.
- Develops AR-712 and AR-701, a cocktail of mAbs in Phase I/II clinical trials for mild to moderate non-hospitalized COVID-19 patients.
Business Model
- Develops and patents fully human monoclonal antibodies (mAbs) targeting life-threatening infections.
- Conducts preclinical and clinical trials to demonstrate the safety and efficacy of its mAb-based therapies.
- Seeks regulatory approval from agencies like the FDA for its products.
- Out-licenses or partners with larger pharmaceutical companies for commercialization and distribution.
Industry Context
Aridis Pharmaceuticals operates within the biotechnology industry, which is characterized by high innovation, long development cycles, and significant regulatory oversight. The increasing prevalence of antibiotic-resistant infections is driving demand for novel therapeutic approaches, creating a significant market opportunity for companies like Aridis that are developing targeted immunotherapies. The competitive landscape includes companies such as AFIB, BTAX, EVLO, HSTC, and ICCT, as well as larger pharmaceutical companies with established infectious disease portfolios. Aridis differentiates itself through its focus on fully human monoclonal antibodies and its pipeline of therapies targeting specific bacterial toxins and pathogens.
Key Customers
- Hospitals and healthcare providers treating patients with severe bacterial infections.
- Patients suffering from lung infections caused by S. aureus alphatoxin.
- Patients with cystic fibrosis experiencing chronic lung infections.
- Pharmaceutical companies seeking to expand their infectious disease portfolios through licensing or partnerships.
Financials
Chart & Info
Aridis Pharmaceuticals, Inc. (ARDS) stock price: $0.00 (+0.00, +0.00%)
Latest News
-
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
benzinga · Jul 17, 2023
-
76 Biggest Movers From Yesterday
benzinga · May 19, 2022
-
15 Stocks Moving in Monday's Pre-Market Session
· Dec 27, 2021
-
Stocks That Hit 52-Week Lows On Thursday
· Oct 10, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ARDS.
Price Targets
Wall Street price target analysis for ARDS.
MoonshotScore
What does this score mean?
The MoonshotScore rates ARDS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
76 Biggest Movers From Yesterday
15 Stocks Moving in Monday's Pre-Market Session
Stocks That Hit 52-Week Lows On Thursday
Leadership: Vu L. Truong
CEO
Vu L. Truong is the Chief Executive Officer of Aridis Pharmaceuticals, Inc. His background includes extensive experience in the biopharmaceutical industry, with a focus on developing and commercializing innovative therapies. He has held leadership positions at various biotechnology companies, where he oversaw research and development, clinical trials, and regulatory affairs. Truong's expertise lies in building and managing teams, securing funding, and driving strategic growth. His educational background includes advanced degrees in science and business.
Track Record: Under Vu L. Truong's leadership, Aridis Pharmaceuticals has advanced its pipeline of mAb-based therapies, including AR-301, into late-stage clinical development. He has overseen the successful completion of several clinical trials and has secured funding to support the company's research and development efforts. Truong has also forged strategic partnerships to expand the company's reach and accelerate the commercialization of its products.
ARDS OTC Market Information
The OTC Other tier represents the lowest tier of over-the-counter (OTC) markets, indicating that Aridis Pharmaceuticals may not meet the minimum financial or regulatory requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited reporting requirements and may not be subject to the same level of scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This can result in less transparency and increased risk for investors compared to exchange-listed companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Disclosure: OTC Other companies may have limited financial reporting requirements, making it difficult to assess their financial health and performance.
- Low Liquidity: Low trading volume and wide bid-ask spreads can make it challenging to buy or sell shares.
- Price Volatility: OTC stocks are often more volatile than exchange-listed stocks, increasing the risk of significant price swings.
- Potential for Fraud: The lack of regulatory oversight increases the risk of fraud and manipulation.
- Going Concern Risk: OTC Other companies may have a higher risk of financial distress or bankruptcy.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Review the company's legal and regulatory compliance.
- Check for any red flags, such as lawsuits or regulatory actions.
- Consult with a financial advisor before investing.
- Experienced Management Team: A management team with a proven track record in the biopharmaceutical industry.
- Patented Technology: Patents on its mAb-based therapies provide a competitive advantage.
- Clinical Trial Progress: Advancement of its product candidates into late-stage clinical development.
- Strategic Partnerships: Collaborations with reputable pharmaceutical companies.
- Independent Audits: Audited financial statements by a reputable accounting firm.
ARDS Healthcare Stock FAQ
What does Aridis Pharmaceuticals, Inc. do?
Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. Their lead product candidate, AR-301, is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing a pipeline of mAb-based therapies targeting various other infectious diseases, including Pseudomonas aeruginosa, Acinetobacter baumannii, respiratory syncytial virus, and chronic lung infections in cystic fibrosis patients. Aridis aims to address the growing need for novel therapies to combat antibiotic resistance and improve patient outcomes.
What do analysts say about ARDS stock?
As of March 15, 2026, there is no available analyst consensus on Aridis Pharmaceuticals (ARDS) stock. Given its OTC Other listing and limited market capitalization, ARDS may not be widely covered by analysts. Investors should conduct their own thorough research and consider the company's financial condition, clinical trial progress, and regulatory outlook before making any investment decisions. Key valuation metrics are currently unavailable, and growth considerations are primarily tied to the successful development and commercialization of its mAb-based therapies.
What are the main risks for ARDS?
Aridis Pharmaceuticals faces several significant risks inherent to the biotechnology industry and its OTC market listing. Clinical trial failures represent a major risk, as negative results could delay or halt product development. Regulatory hurdles and potential rejection of its product candidates also pose a threat. The company's limited financial resources require additional capital to fund ongoing research and development, which could dilute existing shareholders. Competition from established pharmaceutical companies with larger resources and established infectious disease portfolios is another key risk. Furthermore, the OTC Other listing carries additional risks related to limited disclosure, low liquidity, and price volatility.
What are the key factors to evaluate for ARDS?
Aridis Pharmaceuticals, Inc. (ARDS) currently holds an AI score of 42/100, indicating low score. Key strength: Innovative mAb Technology: Expertise in developing fully human monoclonal antibodies.. Primary risk to monitor: Potential: Clinical Trial Failures: Risk of clinical trial failures that could delay or halt product development.. This is not financial advice.
How frequently does ARDS data refresh on this page?
ARDS prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ARDS's recent stock price performance?
Recent price movement in Aridis Pharmaceuticals, Inc. (ARDS) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative mAb Technology: Expertise in developing fully human monoclonal antibodies.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ARDS overvalued or undervalued right now?
Determining whether Aridis Pharmaceuticals, Inc. (ARDS) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ARDS?
Before investing in Aridis Pharmaceuticals, Inc. (ARDS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Investment decisions should be based on individual risk tolerance and financial circumstances.
- This is not investment advice.